Exposure to Novel Parainfluenza Virus and Clinical Relevance in 2 Bottlenose Dolphin (Tursiops truncatus) Populations by Venn-Watson, Stephanie et al.
Parainﬂ  uenza virus (PIV) is a leading cause of respira-
tory infections in humans. A novel virus closely related to 
human and bovine parainﬂ  uenza viruses types 3 (HPIV-3 
and BPIV-3), named Tursiops truncatus parainﬂ  uenza virus 
type 1 (TtPIV-1), was isolated from a dolphin with respira-
tory disease. We developed a dolphin-speciﬁ   c ELISA to 
measure acute- and convalescent-phase PIV antibodies in 
dolphins during 1999–2006 with hemograms similar to that 
of the positive control. PIV seroconversion occurred concur-
rently with an abnormal hemogram in 22 animals, of which 
7 (31.8%) had respiratory signs. Seroprevalence surveys 
were conducted on 114 healthy bottlenose dolphins in Flor-
ida and California. When the most conservative interpreta-
tion of positive was used, 11.4% of healthy dolphins were 
antibody positive, 29.8% were negative, and 58.8% were 
inconclusive. PIV appears to be a common marine mammal 
virus that may be of human health interest because of the 
similarity of TtPIV-1 to BPIV-3 and HPIV-3.
P
arainﬂ  uenza viruses (PIVs) are often associated with 
respiratory illness in terrestrial mammals, including 
croup in humans (1), kennel cough in dogs (2), and bo-
vine respiratory disease in cattle (3). A novel PIV tenta-
tively named Tursiops truncatus parainﬂ  uenza virus type 
1 (TtPIV-1) was cultured from lung tissue in an Atlantic 
bottlenose dolphin (T. truncatus) (4). This animal had re-
spiratory disease including laryngitis, tracheitis, and bron-
chointerstitial pneumonia with mild to moderate growth of 
Candida glabrata. 
Phylogenetic analyses of 2 genomic fragments of 
TtPIV-1 showed that the virus strain was monophyletic 
with, but genetically distinct from, bovine parainﬂ  uenza 
virus 3 (BPIV-3) strains and human parainﬂ  uenza type 3 
(HPIV-3) (4). BPIV-3 is an effective antigenic stimulator in 
humans and is used in human vaccines that protect against 
HPIV-3 (5–7). TtPIV-1 may provide similar protection in 
humans. Dolphins have been recognized as useful marine 
ecosystem sentinels (8), and changes in marine PIV may 
reﬂ  ect changes in terrestrial PIV.
ELISAs have been characterized as the most sensitive 
diagnostic tool to identify rising titers due to PIV-associ-
ated respiratory illness in humans (9). Although ELISA is 
the ideal tool for identifying infections caused by PIV, high 
levels of antigenic cross-reactivity among various PIV sub-
families and other closely related viruses hinder the ability 
for ELISA to determine which type of PIV has infected 
an animal (10,11). In wild marine mammal populations, 
ELISA-based serosurveys for suspected viral or bacterial 
pathogens are common (12–14). Limitations of these stud-
ies include unknown health status of animals or lack of 
paired samples that can differentiate exposures from active 
infections. 
The US Navy Marine Mammal Program (MMP) man-
ages a population of bottlenose dolphins that live in San Di-
ego Bay, California. These animals are provided high-qual-
ity medical and preventive care throughout their lifetime. 
Standardized health data and voluntary blood samples are 
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collected routinely, uniquely enabling MMP to amass rou-
tine physiologic information on dolphins living in a marine 
environment at all age stages. Since 1988, health assess-
ments have been conducted by the Chicago Zoological So-
ciety and collaborators on a free-ranging, resident coastal 
population of bottlenose dolphins in Sarasota Bay, Florida, 
2,500 miles away, as part of the world’s longest running 
study of wild dolphins. Serum samples from this presum-
ably healthy population are archived for use in retrospec-
tive health assessments.
An indirect, dolphin-speciﬁ   c PIV-antibody ELISA 
was developed and applied to archived serum samples col-
lected from MMP dolphins in San Diego (1999–2006) and 
healthy, free-ranging dolphins living near Sarasota (2004–
2005). We used this ELISA to assess the clinical relevance 
of PIV exposure and seroconversion in bottlenose dolphins 
living along US coasts.
Methods
The MMP is routinely reviewed by an Institutional An-
imal Care and Use Committee (IACUC) and Navy Bureau 
of Medicine; the MMP is accredited by the Assessment and 
Accreditation of Laboratory Care International. All sample 
collection protocols for the Sarasota wild dolphin popula-
tion were approved by the University of Florida IACUC 
(IACUC no. C233).
San Diego, California
Blood samples from MMP dolphins were initially col-
lected by venipuncture from animals trained either to pres-
ent their tail for sampling in the water or to rest on a foam 
mat during a routine physical examination out of the water. 
Samples were collected from the caudal peduncle vein by 
using a 20- or 21-gauge, 1.5-inch Vacutainer needle (Bec-
ton Dickinson Vacutainer Systems, Rutherford, NJ, USA) 
or from a ﬂ  uke vein by using a 21-gauge, 1-inch butterﬂ  y 
needle. Blood was collected into a Vacutainer serum sepa-
rator tube or a Vacutainer EDTA (K3) tube for serum chem-
istries and complete blood counts, respectively.
Samples for chemistry analysis were centrifuged with-
in 2 h of collection. Centrifugation was performed at 3,000 
rpm at 21°C for 10 min. Fibrin clots were removed, and 
serum was transferred to a 5-mL plastic submission tube. 
Whole blood was collected in EDTA Vacutainer tubes. All 
samples were sent on wet ice by courier to Quest Diagnos-
tic Laboratories in San Diego.
Automated hematologic analyses were conducted by 
Quest Diagnostic Laboratories with the Coulter LH 1500 
Series (Beckman Coulter, Inc., Fullerton, CA, USA). The 
Fisherbrand Dispette 2 (Fisher Scientiﬁ  c, Pittsburgh, PA, 
USA), correlating with the Westergren method, was used 
in house to determine 60-min erythrocyte sedimentation 
rates (ESRs) from 1 mL EDTA whole blood. Remaining 
serum from these samples was archived at –80°C at the 
MMP facility at the time of initial blood collection.
Upon completed development of the PIV-antibody 
ELISA, the archived, frozen serum samples were shipped 
frozen overnight to the laboratory for PIV-antibody analy-
sis. Total leukocyte count, absolute neutrophils, absolute 
lymphocytes, absolute monocytes, absolute eosinophils, 
and ESR results were incorporated into the retrospective 
PIV seroprevalence study and linked to animal age, sex, 
clinical signs, and PIV-antibody ELISA results.
Sarasota Bay, Florida
Blood samples from free-ranging dolphins were ob-
tained as part of a long-term health assessment conducted 
near Sarasota, involving a multigenerational resident popu-
lation of ≈150 dolphins (8). Most of these dolphins are rec-
ognizable; are of known age, gender, and maternal lineage; 
and medical histories have been recorded for many years. 
Small groups of dolphins were encircled with a 5,000-m 
long × 5-m deep seine net in shallow water (<1.8 m). Each 
dolphin was shaded, kept cool and wet, and carefully moni-
tored for signs of discomfort by 1 to 3 veterinarians expe-
rienced with cetaceans. The veterinary staff monitored the 
dolphin’s respiration rate and quality, responsiveness to ex-
ternal stimuli, mental alertness, skin temperature, and heart 
rate to evaluate the animal’s comfort level and immediate 
health status. Blood samples were drawn from the ventral 
ﬂ  uke vasculature by a 19-gauge × ¾-inch butterﬂ  y catheter 
with a multisample adaptor (Becton Dickinson), which al-
lowed the blood collection tubes to be ﬁ  lled directly from 
the venipuncture set.
ELISA Development
Antigen Production
Archived TtPIV-1 was propagated in BSC40 cells as 
previously described (15). Uninfected BSC40 cells were 
cultured as negative controls. When >90% of the infected 
monolayers showed cytopathic effect (CPE), all infected 
and uninfected cultures were harvested and centrifuged for 
15 min at 1,500 rpm, and the supernatant media was re-
moved. The remaining cell pellets were freeze-thawed 3× 
and centrifuged for 15 min at 3,000 rpm. The cell pellet 
was discarded, and the supernatant cell lysates were pooled 
for use as antigen in the ELISA. The protein concentration 
of the infected and uninfected cell lysates was determined 
by using a modiﬁ  ed Bradford assay for ELISA, after which 
the cell lysates were diluted in phosphate-buffered saline 
(PBS) to the desired coating concentration.
Optimization of ELISA Parameters
A serum sample collected postmortem from the case 
dolphin was used as the positive reference serum. A nega-
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tive reference serum sample was collected from an immu-
nologically naive neonate bottlenose dolphin that had not 
yet nursed. The positive and negative reference serum sam-
ples were used to optimize the ELISA conditions. All assay 
parameters were varied (working volume 50–100 μL; coat-
ing concentration 1–20 μg/mL; serum dilution 1:50–1:400; 
developing time 15–60 min), and the assay conditions with 
the highest ratio of the optical density at 405 nm (OD405) of 
positive reference serum sample to the OD405 of negative 
reference serum sample were selected. The conditions of 
the optimized ELISA protocol were as follows. Wells of 
a high protein-binding microplate (Nunc Maxisorp, Fisher 
Scientiﬁ  c) were coated with 50 μL of infected or uninfect-
ed cell lysates at 5 μg/mL in PBS and were left to adsorb 
overnight at 4°C. After this and each subsequent step, all 
wells were washed 3× with PBS with 0.05% Tween by us-
ing an automated EL 404 microplate washer (Biotek Instru-
ments, Winooski, VT, USA). After washing, all wells were 
blocked with 300 μL of Superblock blocking buffer (Pierce, 
Rockford, IL, USA) in PBS with sodium azide (PBS/Az), 
after which the dolphin serum samples were applied (1:500 
in 1% bovine serum albumin [BSA] in PBS/Az). All sera 
were applied in triplicate to wells that were coated with 
either infected or uninfected cell lysate antigen. The posi-
tive and negative control sera were included on each plate. 
A biotinylated monoclonal antibody speciﬁ  c for bottlenose 
dolphin IgG (15) was used at a concentration of 5 μg/mL (in 
1% BSA in PBS/Az) as the secondary reagent for the detec-
tion of bound antibodies. Each step of the ELISA was left 
to incubate with gentle agitation (Nutator; Adams, Fisher 
Scientiﬁ  c) for 1 h at ≈22°C. Finally, 1.0 mg/mL p-nitrophe-
nyl phosphate (Sigma, St. Louis, MO, USA) substrate was 
added. The OD405 was recorded 60 min after addition of 
the substrate by using a Spectramax 250 microplate reader 
(Molecular Devices, Sunnyvale, CA, USA). For analysis, 
the mean OD405 of the triplicate readings on the uninfected 
antigen was subtracted from the mean OD405 of the tripli-
cate readings by using the infected antigen. All results were 
presented as OD405 ratios, deﬁ  ned as the OD405 reading of 
the unknown samples divided by the OD405 reading of the 
positive control sample for that plate.
Cut-off Values, Deﬁ  nitions, and Data Analysis
All data were analyzed with SAS software (Release 
8e; SAS Institute, Inc., Cary, NC, USA). p values <0.01 
were deﬁ  ned as signiﬁ  cant.
PIV Seroconversion
Archived hematologic and clinical observation data 
(1999–2006) were mined to identify dolphins with hemo-
grams similar to that of the positive control animal, includ-
ing a neutrophilic, monocytic leukocytosis or a high ESR, 
as deﬁ  ned by MMP reference ranges (16). Archived serum 
samples collected within 60 days before, during, and <90 
days after an inﬂ  ammatory hemogram or clinical illness 
from suspected PIV cases were subsequently analyzed for 
PIV antibodies with the dolphin-speciﬁ  c ELISA. PIV sero-
conversion was deﬁ  ned as a >4-fold increase in PIV anti-
body OD405 level within a 3-month period.
Analyses were conducted to describe frequencies of 
abnormal clinicopathologic values and clinical signs among 
PIV seroconversion cases from 60 days before the highest 
OD405 ratio to 30 days after the highest OD405 ratio. Median 
clinicopathologic blood values were calculated among PIV 
seroconversion cases by using the serum sample with the 
highest leukocyte count from each identiﬁ  ed animal (e.g., 
the blood sample most likely representing the most severe 
phase of disease).
Seroprevalence among Healthy Populations
Serum samples collected during July to December 
2006 from 58 MMP bottlenose dolphins in San Diego and 
samples collected during 2003–2005 from 56 free-ranging 
bottlenose dolphins living near Sarasota were analyzed for 
PIV antibodies. Because only 1 positive control animal had 
been identiﬁ  ed, a conservative interpretation of ELISA re-
sults was adopted. Samples with an OD405 ratio >1.0 (se-
ropositive) contained an antibody level at least as high as 
the positive control’s highest antibody level during the time 
of PIV infection. Samples with an OD405 ratio of 0.0 (se-
ronegative) contained an anti-PIV antibody level that was 
less than or equal to the negative control. OD405 ratios >0 
and <1 were categorized as inconclusive. Midrange values 
were used to compare mean OD405 ratios by population lo-
cation, age, and sex. Midrange values were also used to 
assess changes within 1 animal over time (see Methods, 
PIV Seroconversion).
Descriptive statistics were used to determine the preva-
lence of PIV-seropositive, -seronegative, and -inconclusive 
animals among the 2 study populations. To assess the clini-
cal relevance of PIV exposure among presumably healthy 
dolphins, mean values of hematologic and serum biochem-
ical inﬂ  ammatory indicators (leukocyte counts and ESR) 
were subsequently compared between PIV-seropositive 
and -seronegative animals in the MMP 2006 population by 
using analysis of covariance (ANCOVA) with a general lin-
ear model to control for varying numbers of samples, age, 
and sex of animals. Age and sex were controlled covariates 
because of the previously documented effects of age and 
sex on healthy, normal reference ranges in dolphins (16). 
A type I sum of squares p value was used to determine sig-
niﬁ  cance. Mean comparisons were reported by using least 
squares means when controlling for covariates.
PIV-antibody levels were compared between healthy 
MMP dolphins in San Diego and free-ranging dolphins liv-
ing near Sarasota. Differences in age and sex between the 2 
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study populations were analyzed by using a general linear 
model (PROC GLM; CLASS population; MODEL age = 
population; MEANS population) and a Mantel-Haenszel 
χ2 test, respectively. Mean OD405 levels were compared by 
population, age, and sex (controlling for age due to identi-
ﬁ  ed differences in ages between the 2 populations) by using 
ANCOVA with a general linear model to control for vary-
ing numbers of samples by animal (PROC GLM Overview, 
SAS Online Doc, Version 8, SAS Institute, Inc.).
Results
Positive Control Case
PIV serum antibody OD405 levels were determined in a 
dolphin from which TtPIV-1 was successfully isolated from 
antemortem and postmortem lung samples. Low PIV anti-
body levels appeared to be present 300 days before illness, 
and rising antibody levels were detected during the course of 
TtPIV-1–associated respiratory illness (Figure 1).
PIV Seroconversion
PIV antibody levels were determined in 588 serum 
samples collected during 1999–2006 from 58 selected 
MMP bottlenose dolphins before, during, and after an in-
ﬂ  ammatory hemogram similar to that of the positive con-
trol. Within this sample set, 22 dolphins were identiﬁ  ed that 
seroconverted within a 3-month period (examples, Figure 
2, panels A–C). Eleven (50%) of the dolphins that sero-
converted were female; median age was 22.2 years (range 
0.3–43 years).
As expected because of the selection criteria for sus-
pected cases, dolphins with PIV seroconversion had a neu-
trophilic leukocytosis (18, 81.8%) or high ESR (16, 72.7%). 
Other clinicopathologic abnormalities that were present in 
at least half of the case dolphins included hyperglobulin-
emia, monocytosis, thrombocytosis, and high alanine ami-
notransferase (ALT) levels (Tables 1, 2).
Of 22 dolphins that seroconverted, 5 (22.7%) main-
tained normal behavior and appetite, and 17 (77.3%) had 
at least 1 clinical sign. The most commonly reported be-
havioral abnormalities were decreased appetite (12, 54.5%) 
and lethargy (10, 45.5%). Veterinary observations also in-
cluded respiratory (7, 31.8%) and ocular (5, 22.7%) clinical 
signs (Table 3). Respiratory signs included ventral left lung 
consolidation, pleuritis, tachypnea, coughing, and abnor-
mal blowhole ﬂ  uid. Ocular clinical signs were reported as 
bilateral or unilateral blepharospasm, intermittent squint-
ing, or corneal opacities. Other clinical signs were diffuse, 
miliary skin or mucosal lesions (2 dolphins) and orange-
yellow liquid feces and excessive ﬂ  atulence (2 dolphins).
400  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 3, March 2008
Figure 1. Sample series of parainﬂ   uenza virus (PIV) antibody 
optical density in the positive control bottlenose dolphin (Tursiops 
truncatus) during time of respiratory illness and multiple positive 
viral isolations from grossly affected lung.
Figure 2. Evidence of active parainﬂ   uenza virus (PIV) infection 
in bottlenose dolphins (Tursiops truncatus) with inﬂ  ammatory 
hemograms or clinical illness. A) PIV antibody optical density at 
405 nm (OD405) ratios in a 3-year-old female bottlenose dolphin; B) 
PIV antibody OD405 ratios in a 26-year-old male bottlenose dolphin; 
C) PIV antibody OD405 ratios in a 22-year-old male bottlenose 
dolphin.Parainﬂ  uenza Virus in Bottlenose Dolphins
Of 13 dolphins that had clinical signs and recovered, 
the average duration of clinical illness was 9.8 days (range 
1–40 days). Four dolphins had PIV antibody seroconver-
sion within 30 days of death, but the presence of TtPIV-1 
was not conﬁ  rmed on virus culture from any animal tissues 
upon necropsy except from the positive control dolphin. Of 
these 4 dolphins, 2 died from bacterial pneumonia conﬁ  rmed 
by laboratory culture and histologic examination, and 1 had 
mild to moderate growth of Candida glabrata from lung 
samples. All 4 animals had a mild to moderate tracheitis or 
laryngitis not explained by ﬁ  nding intralesional bacterial or 
fungal infection upon histopathologic examination.
Population Seroprevalence
Comparisons of age and sex distribution among the 2 
dolphin populations are provided in Table 4. The median 
age of dolphins was 15.5 years (range 0.2–49.2). Sex was 
determined for 110 dolphins; of these, 50% were female.
Of 114 clinically healthy dolphins tested for PIV 
antibodies, 13 (11.4%) were positive, 34 (29.8%) were 
negative, and 67 (58.8%) were inconclusive (0 <OD405 
ratio <1.0). Mean and median PIV OD405 ratios were 0.4 
(standard deviation = 0.4) and 0.2 (range 0.0–2.8), respec-
tively. There were no signiﬁ  cant differences in OD405 ratio 
by age (p = 0.2) or sex (females = 0.33, males = 0.43, p 
= 0.3). When Florida free-ranging healthy dolphins were 
compared with San Diego managed healthy dolphins, there 
were no signiﬁ  cant differences in mean PIV OD405 ratios 
(p = 0.6) or percentages of animals categorized as nega-
tive, positive, or inconclusive (Table 4; p = 0.5). Among 
the 2006 MMP healthy dolphin serosurvey population, no 
signiﬁ  cant differences were identiﬁ  ed when hematologic 
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Table 1. Frequencies of abnormal hematologic and inflammatory indicator values in bottlenose dolphins (Tursiops truncatus) within  
60 d before and 30 d after PIV antibody seroconversion (n = 22)* 
Blood variable
Adult dolphin 
reference range Median value (range), cases
No. (%) cases below 
reference range
No. (%) cases above 
reference range
Leukocytes, cells/PL 4,275–10,089 12,950 (5,700–38,800) 2 (9.1) 18 (81.8)
HCT, % 38–46 39 (29–50) 11 (50.0) 0
Platelets, cells/PL 55,000–143,000 116,000 (25,000–333,000) 6 (27.3) 11 (50.0)
Neutrophils, cells/PL 2,737–7,570 9,750 (3,760–36,470) 2 (9.1) 18 (81.8)
Lymphocytes, cells/PL 270–1,500 1,425 (290–5,210) 3 (13.6) 7 (31.8)
Monocytes, cells/PL 0–576 300 (0–3, 080) NA 11 (50.0)
Eosinophils, cells/PL 78–1,792 900 (0–3,000) 8 (36.4) 3 (13.6)
ESR, mL/60 min 0–18 22 (1–131) NA 16 (72.7)
Iron, Pg/dL 92–300 193 (22–1,036) 8 (36.4) 9 (40.9)
*PIV, parainfluenza virus; HCT, hematocrit; NA, not available; ESR, erythrocyte sedimentation rate. 
Table 2. Frequencies of abnormal serum biochemical values in bottlenose dolphins (Tursiops truncatus) within 60 d before and 30 d 
after PIV antibody seroconversion (n = 22)* 
Blood variable
Adult dolphin 
reference range
Median value (range), 
cases
No. cases below 
reference range (%)
No. cases above 
reference range (%)
Protein, g/dL 6.2–7.6 7.1 (5.7–9.6) 4 (18.2) 12 (54.5)
Albumin, g/dL 3.9–4.9 4.2 (3.4–5.1) 6 (27.3) 2 (9.1)
Globulin, g/dL 2.1–3.1 3.0 (1.7–5.0) 2 (9.1) 12 (54.5)
Glucose, mg/dL 85–144 110 (70–214) 7 (31.8) 9 (40.9)
Sodium, mEq/L 153–159 156 (127–169) 8 (36.4) 0
Chloride, mEq/L 115–125 118 (109–134) 12 (54.5) 0
Potassium, mEq/L 3.5–4.1 3.8 (3.0–7.5) 5 (22.7) 10 (45.5)
Calcium, mg/dL 8.3–9.7 9.1 (6.6–10.8) 3 (13.6) 9 (40.9)
BUN, mg/dL 36–59 48 (29–76) 8 (36.4) 6 (31.8)
Creatinine, mg/dL 1.2–2.0 1.3 (0.7–2.4) 7 (31.8) 4 (18.2)
Uric acid, mg/dL 0.0–0.7 0.2 (0.0–1.8) NA 8 (36.4)
LDH, U/L 270–494 399 (247–1672) 0 10 (45.5)
AST, U/L 118–398 228 (111–987) 0 9 (40.9)
ALT, U/L 13–54 33 (15–541) 0 11 (50.0)
GGT, U/L 21–48 39 (18–876) 0 10 (45.5)
Carbon dioxide, mEq/L 17–28 24 (9–34) 3 (13.6) 4 (18.2)
Inorganic phosphate, mg/dL 3.9–5.9 5.1 (3.2–7.5) 6 (27.3) 9 (40.9)
Alkaline phosphatase, U/L 158–556 240 (36–1070) 8 (36.4) 3 (13.6)
Cholesterol, mg/dL 153–262 202 (115–382) 9 (40.9) 5 (22.7)
Triglyceride, mg/dL 11–175 95 (27–667) 0 8 (36.4)
CPK, U/L 51–183 122 (24–596) 5 (22.7) 9 (40.9)
*PIV, parainfluenza virus; BUN, blood urea nitrogen; NA, not available; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; GGT, gamma-glutamyl transpeptidase; CPK, creatine phosphokinase. RESEARCH
indicators of inﬂ  ammation among healthy PIV antibody–
positive dolphins were compared with PIV antibody–nega-
tive dolphins (Table 5).
Discussion
Using an indirect dolphin-speciﬁ  c antibody ELISA, 
we demonstrated an increase in PIV serum antibodies dur-
ing culture-conﬁ   rmed TtPIV-1 respiratory illness in an 
adult bottlenose dolphin. Although ELISA has been rec-
ognized as the most sensitive indicator of PIV infections 
in human populations (9), virus isolation and genotyping 
are needed to conﬁ  rm which type of PIV is associated with 
an infection (10). As such, antibody ELISA results in our 
study were interpreted as dolphin immune responses to PIV 
or a closely related virus (e.g., a mumps-like virus).
We report 21 additional dolphins in which PIV anti-
body seroconversion occurred within 3 months of an ab-
normal hemogram similar to that of the positive control 
animal during 1999–2006. Approximately 23% of these 
dolphins did not have overt clinical signs, indicating that 
PIV infections may affect hematologic values without af-
fecting animal behavior. Further, no signiﬁ  cant differences 
in inﬂ  ammatory indicators were identiﬁ  ed when PIV an-
tibody–seropositive and –seronegative animals were com-
pared in our cross-sectional serosurvey of healthy animals. 
Subclinical BPIV-3 infections are frequent in cattle popu-
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Table 3. Clinical signs noted in selected bottlenose dolphins (Tursiops truncatus) within 60 d before and 30 d after PIV antibody 
seroconversion and an abnormal hemogram (n = 22)*† 
Animal Clinical signs Decreased appetite Lethargy
Respiratory 
signs Ocular signs Epidermal signs GI signs
A
BX X X
C
DX X
EXX X X
FXX
GXX X
HXX X X X
IX X X X
JX X X X
KXX X X
L
M
NX X X X
O
PXX X
QX
RX X
SXX X X
TXX X
UXX X X
V X  X X
Total 17 (77.3%) 12 (54.5%) 10 (45.5%) 7 (31.8%) 5 (22.7%) 2 (9.1%) 2 (9.1%)
*PIV, parainfluenza virus; GI, gastrointestinal. 
†No viruses were cultured from clinical samples collected from these animals, with the exception of the positive control dolphin, and 2 dolphins had 
culture-confirmed bacterial pneumonia concurrent with PIV seroconversion. 
Table 4. Comparisons of age, sex, and PIV antibody levels among 2 healthy bottlenose dolphin (Tursiops truncatus) populations (n = 
114)
Descriptor 
Free-ranging dolphins, Sarasota, 
Florida (n = 56) 
Managed dolphins,  
San Diego, California (n = 58)  p value 
Mean age, y  11.5 20.7 <0.0001
Sex, % 
 Female  45.6 54.7 0.3
 Male  54.4 45.3
Mean PIV antibody OD405 ratio*  0.42 0.36 0.6
PIV result, %  0.5
 Negative  33.9 25.9
 Equivocal  58.9 58.6
 Positive  7.1 15.5
*PIV, parainfluenza virus; OD405, optical density at 405 nm. Parainﬂ  uenza Virus in Bottlenose Dolphins
lations (17). In a case-control study comparing acute- and 
convalescent-phase serum samples among calves with re-
spiratory disease and calves that were clinically normal, the 
incidence of BPIV-3 seroconversion was actually higher in 
clinically normal calves (18). 
In our survey involving dolphins that seroconverted 
within 3 months of an abnormal hemogram, clinical signs 
were most often nonspeciﬁ  c and limited to lethargy and de-
creased appetite lasting an average of 9–10 days. Of animals 
that seroconverted, 32% had respiratory clinical signs, and 
3 of 4 animals that died within 30 days of seroconversion 
had intralesional bacterial or fungal pathogens in lung tis-
sue. Further evidence of primary PIV infections in animals 
that died from bacterial or fungal pneumonia was inﬂ  amed 
laryngeal or tracheal tissue without intracellular bacterial 
or fungal pathogens. Despite conﬁ  rmed bacterial or fungal 
pneumonia in these animals, pathologists’ interpreted the 
tracheitis and laryngitis to be of possible viral origin. In 
terrestrial mammals, PIV most commonly affects the upper 
and lower respiratory tract (1–3,9), and frequent conditions 
include tracheitis and laryngitis. Further, PIV infections are 
commonly associated with bacterial or fungal coinfections 
in terrestrial mammals (19–21).
In our study, nonrespiratory signs associated with PIV 
seroconversion involved the ocular, epidermal, and gas-
trointestinal systems. Additionally, 50% of dolphins with 
PIV seroconversion had high ALT levels not associated 
with medications, indicating potential hepatic involvement. 
Similarly, nonrespiratory clinical signs reported in a study 
involving 46 human patients with PIV virus infections in-
cluded conjunctivitis, exanthema, oral mucosal lesions, di-
arrhea, and increased levels of transaminases (22).
Lacking in all active case dolphinss, except the posi-
tive control, was culture of PIV from clinical or postmor-
tem samples. In humans, reported HPIV-3 viral culture 
success rates from clinical samples can range from 42% to 
50% (23,24), and detecting PIV by looking for CPE is not 
considered reliable or useful (9). The diagnostic laboratory 
we routinely used to culture viruses from MMP samples 
relied primarily upon CPE in monkey kidney cell lines over 
multiple passages. To improve the likelihood of isolating 
PIV during active infections in bottlenose dolphins, diag-
nostic workups should include PCRs and indirect immu-
noﬂ  uorescent-antibody assays (IFAs), as these tools have 
proven effective for rapidly identifying PIV cases in other 
species (25,26).
In our seroprevalence study involving 114 clinically 
healthy dolphins, we demonstrated that 11.4% had PIV 
antibodies at least as high as our positive control, and 70% 
had PIV antibodies higher than our negative control. No 
signiﬁ  cant differences in PIV antibody levels were found 
when comparing dolphin location, age, or sex. Similar 
ﬁ  ndings regarding equivalent PIV exposures by age, sex, 
and geographic location have been reported in humans (9) 
and cattle (27). High rates of PIV infection among these 
populations support incomplete immunization with in-
fections and high rates of reinfection throughout life (9). 
Serologic studies have demonstrated common PIV expo-
sure among wild hooved species in Alaska (67%) (28), 
the central Italian Alps (17%) (29), Argentina (43%) (30), 
Alberta (49%) (31), South Africa (25%) (32), and Quebec 
(82%–84%) (33). 
The primary limitation of our study was interpretation 
of PIV antibody levels based upon 1 positive control. To 
compensate for the limitation of positive controls among 
marine mammal samples, we applied conservative deﬁ  ni-
tions for positive and negative ELISA results and tested for 
signiﬁ  cant changes in antibody levels in the same animal 
over time. Use of PCR and IFA as standard assays on pro-
spective samples will help to increase the number of posi-
tive controls for future studies (22).
TtPIV-1 is a novel virus most closely related to bo-
vine PIV3 (BPIV-3) (4), and attenuated BPIV-3 has been 
demonstrated as a safe and effective vaccine against hu-
man PIV3 (HPIV-3) in human populations (34,35). Given 
the genetic similarity of TtPIV-1 to BPIV-3 and HPIV-
3, TtPIV-1 may provide therapeutic beneﬁ   t to human 
populations.
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